Skip to content

The Impact of Postoperative TEAS on the Incidence of LARS and Gastrointestinal Recovery in Rectal Cancer Patients after stoma closure

The Impact of Postoperative TEAS on the Incidence of LARS and Gastrointestinal Recovery in Rectal Cancer Patients after stoma closure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001515
Enrollment
Unknown
Registered
2026-06-17
Start date
2026-06-24
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LARS

Interventions

TEAS group:Transcutaneous Electrical Acupoint Stimulation and postoperative management
Sham TEAS group:Sham Transcutaneous Electrical Acupoint Stimulation and postoperative management

Sponsors

Institute Of Basic Research In Clinical Medicine,China Academy Of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: a. Aged between 35 and 75 years; b. Cases undergoing radical resection or low anterior resection of rectal cancer with preservation of the anal sphincter, followed by stoma reversal; c. Karnofsky Performance Status (KPS) of =60, or Eastern Cooperative Oncology Group (ECOG) performance status of =2; d. No history of acupuncture or transcutaneous electrical acupoint stimulation (TEAS) within the past 3 months; e. Informed consent from the patient or their family.

Exclusion criteria

Exclusion criteria: a Patients with prior segmental colectomy or synchronous resection for double primary colorectal cancers, in addition to rectal resection; b Those with preoperative imaging or digital rectal examination suggesting anastomotic stricture, ulceration, or fistula; c Patients with a diagnosis of ulcerative colitis, Crohn's disease, or melanosis coli; d Individuals with significant comorbidities involving the heart, brain, lungs, liver, kidneys, or hematologic system, psychiatric disorders, or current use of glucocorticoids or immunosuppressive agents; e Patients with implanted cardiac pacemakers or other electronic implantable devices; f Patients with skin lesions, open wounds, or dermatological abnormalities at the acupoint sites; g Participants currently enrolled in another clinical trial.

Design outcomes

Primary

MeasureTime frame
Incidence of severe LARS in the two groups at 1, 2, and 3 months after stoma reversal;time to first flatus;

Secondary

MeasureTime frame
time to first feces;Severity of nausea, bloating, and pain;I-FEED Score;Wexner Score for Fecal Incontinence;patient reported bowel symptoms;Fecal Incontinence Quality of Life Questionnaire (FIQL);Use of analgesics;

Countries

China

Contacts

Public ContactWang Mengqi

Institute Of Basic Research In Clinical Medicine,China Academy Of Chinese Medical Sciences

wangmqtcm@163.com13261962867

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026